In The News

Ropes & Gray Advises on 3 of the top 5 and 7 of the top 15 Biopharmaceutical Licensing Deals in 2020

Practices: Intellectual Property, Intellectual Property Transactions, IP Structuring in M&A, Spinouts & Reorganizations, IP-Backed Finance, Strategic Commercial Agreements, Life Sciences, Life Sciences Licensing, Collaborations & Joint Ventures, Digital Health, Capital Markets, Health Care, Health Care Finance & Restructuring

Ropes & Gray led all law firms by representing clients in three of the top five, and seven of the top 15 biopharmaceutical licensing deals measured by deal value, according to an analysis published in Fierce Biotech here. Five different Ropes & Gray licensing partners advised clients in these top deals, with Ropes & Gray partner Hannah Freeman notably representing clients in five of the 15– a full third of the top 15 deals of 2020. Among the deals Ropes & Gray was involved in were the following:

  • uniQure N.V. in a licensing agreement worth over $1.6 billon to provide biopharmaceutical company CSL Behring with exclusive global rights to uniQure’s investigational gene therapy for patients with hemophilia B. IP transactions partners Hannah Freeman and David McIntosh (both of Boston) represented Amsterdam-based gene therapy company uniQure N.V.
  • Takeda Pharmaceutical Company in a licensing collaboration with Neurocrine Biosciences to develop and commercialize potential therapies for psychiatric disorders in a deal valued at more than $2 billion, led by IP transactions partner Hannah Freeman.
  • Blackstone IP transactions partners Melissa Rones and Abigail Gregor and M&A partner Michael Beauvais (all of Boston) advised Blackstone.
Cookie Settings